• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effect of a Somatostatin Analogue on the Vasopressin Pathway in Patients With ADPKD.

作者信息

Messchendorp A Lianne, Kramers Bart J, Spithoven Edwin M, Stade Katrin, Meijer Esther, Gansevoort Ron T

机构信息

Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

BRAHMS GmbH, Hennigsdorf, Germany.

出版信息

Kidney Int Rep. 2019 May 16;4(8):1170-1174. doi: 10.1016/j.ekir.2019.04.027. eCollection 2019 Aug.

DOI:10.1016/j.ekir.2019.04.027
PMID:31440707
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6698293/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91e/6698293/1b7545f85000/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91e/6698293/1b7545f85000/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e91e/6698293/1b7545f85000/gr1.jpg

相似文献

1
Effect of a Somatostatin Analogue on the Vasopressin Pathway in Patients With ADPKD.生长抑素类似物对常染色体显性多囊肾病患者血管加压素途径的影响
Kidney Int Rep. 2019 May 16;4(8):1170-1174. doi: 10.1016/j.ekir.2019.04.027. eCollection 2019 Aug.
2
Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.血浆生长抑素与常染色体显性遗传多囊肾病患者疾病严重程度和进展的关系。
BMC Nephrol. 2018 Dec 19;19(1):368. doi: 10.1186/s12882-018-1176-y.
3
Somatostatin centrally inhibits vasopressin secretion during haemorrhage.生长抑素在中枢抑制出血期间的血管加压素分泌。
Brain Res. 1987 Dec 8;436(1):199-203. doi: 10.1016/0006-8993(87)91577-0.
4
Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.血管加压素、 copeptin 和肾功能正常的常染色体显性多囊肾病患者的肾浓缩能力。
Clin J Am Soc Nephrol. 2012 Jun;7(6):906-13. doi: 10.2215/CJN.11311111. Epub 2012 Apr 19.
5
[ADPKD treatment: Tolvaptan and Octreotide].[常染色体显性多囊肾病的治疗：托伐普坦和奥曲肽]
G Ital Nefrol. 2019 Dec 9;36(6):2019-vol6.
6
Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.碱性磷酸酶可预测生长抑素类似物治疗期间多囊肝病的反应：一项汇总分析
Liver Int. 2016 Apr;36(4):595-602. doi: 10.1111/liv.12986. Epub 2015 Nov 9.
7
Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial.常染色体显性多囊肾病中左心室功能障碍和奥曲肽长效释放剂的作用：ALADIN 试验的横断面和纵向亚研究。
Int J Cardiol. 2019 Jan 15;275:145-151. doi: 10.1016/j.ijcard.2018.10.063. Epub 2018 Oct 22.
8
Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation.常染色体显性多囊肾病与渗透压调节的中枢和肾源缺陷有关。
Kidney Int. 2012 Nov;82(10):1121-9. doi: 10.1038/ki.2012.225. Epub 2012 Jun 20.
9
Inhibition by somatostatin of the vasopressin-stimulated adenylate cyclase in a kidney-derived line of cells grown in defined medium.生长在限定培养基中的肾源细胞系中，生长抑素对血管加压素刺激的腺苷酸环化酶的抑制作用。
FEBS Lett. 1984 Apr 24;169(2):133-7. doi: 10.1016/0014-5793(84)80304-x.
10
TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.托伐普坦在重症新生儿常染色体显性多囊肾病（ADPKD）中的应用：药学挑战
Arch Dis Child. 2016 Sep;101(9):e2. doi: 10.1136/archdischild-2016-311535.61.

引用本文的文献

1
Interventions for preventing the progression of autosomal dominant polycystic kidney disease.用于预防常染色体显性遗传性多囊肾病进展的干预措施。
Cochrane Database Syst Rev. 2024 Oct 2;10(10):CD010294. doi: 10.1002/14651858.CD010294.pub3.
2
Copeptin levels increase in response to both insulin-induced hypoglycemia and arginine but not to clonidine: data from GH-stimulation tests.copeptin水平在胰岛素诱导的低血糖和精氨酸刺激下均升高，但在可乐定刺激下不升高：来自生长激素刺激试验的数据。
Endocr Connect. 2023 Sep 27;12(11). doi: 10.1530/EC-23-0042. Print 2023 Nov 1.
3
Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study.

本文引用的文献

1
Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.托伐普坦联合帕瑞肽在 PKD1 模型中显示出增强的疗效。
J Am Soc Nephrol. 2015 Jan;26(1):39-47. doi: 10.1681/ASN.2013121312. Epub 2014 Jul 3.
2
Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.长效生长抑素类似物对常染色体显性多囊肾病（ALADIN）患者肾脏和囊肿生长的影响：一项随机、安慰剂对照、多中心试验。
Lancet. 2013 Nov 2;382(9903):1485-95. doi: 10.1016/S0140-6736(13)61407-5. Epub 2013 Aug 21.
3
Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.
噻嗪类利尿剂和常染色体显性遗传性多囊肾病的疾病进展速度：一项观察性研究。
Nephrol Dial Transplant. 2021 Sep 27;36(10):1828-1836. doi: 10.1093/ndt/gfaa150.
生长抑素类似物治疗严重多囊肝疾病：2 年后的结果。
Nephrol Dial Transplant. 2012 Sep;27(9):3532-9. doi: 10.1093/ndt/gfs152. Epub 2012 Jul 6.
4
The long-term outcome of patients with polycystic liver disease treated with lanreotide.多囊肝患者接受兰瑞肽治疗的长期疗效。
Aliment Pharmacol Ther. 2012 Jan;35(2):266-74. doi: 10.1111/j.1365-2036.2011.04923.x. Epub 2011 Nov 24.
5
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.兰瑞肽可减小多囊肝体积：一项随机、双盲、安慰剂对照试验
Gastroenterology. 2009 Nov;137(5):1661-8.e1-2. doi: 10.1053/j.gastro.2009.07.052. Epub 2009 Jul 29.
6
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease.长效生长抑素治疗常染色体显性遗传性多囊肾病的安全性和有效性。
Kidney Int. 2005 Jul;68(1):206-16. doi: 10.1111/j.1523-1755.2005.00395.x.
7
Somatostatin as a modulator of distal nephron water permeability.
Clin Sci (Lond). 1993 Apr;84(4):455-60. doi: 10.1042/cs0840455.
8
Effect of somatostatin on renal function.生长抑素对肾功能的影响。
Br Med J (Clin Res Ed). 1986 Jun 28;292(6537):1701-2. doi: 10.1136/bmj.292.6537.1701.
9
Somatostatin and water excretion in man: an intrarenal action.生长抑素与人体水排泄：一种肾内作用。
Clin Endocrinol (Oxf). 1985 Aug;23(2):169-74. doi: 10.1111/j.1365-2265.1985.tb00212.x.
10
Interaction of somatostatin with PTH and AVP: renal effects.生长抑素与甲状旁腺激素及抗利尿激素的相互作用：对肾脏的影响
Am J Physiol. 1979 Nov;237(5):E428-36. doi: 10.1152/ajpendo.1979.237.5.E428.